Sign in Subscribe
HIV

Lenacapavir: A Twice-Yearly Injectable for HIV Preexposure Prophylaxis Demonstrates Efficacy and Safety

Strategic Insights

— 2 min read

Current study results on Immune System Diseases and Conditions - HIV/AIDS have been published, investigating the efficacy and safety of lenacapavir for the prevention of HIV-1 infection. Research obtained through August 2025 using search terms lenacapavir, GS-CA1, GS-6207, capsid inhibitor, preexposure prophylaxis, and PrEP demonstrated that lenacapavir, administered through subcutaneous injection, uses a novel mechanism for HIV prevention. This research concluded that lenacapavir arms demonstrated superior efficacy for prevention against a background HIV incidence rate across a variety of populations and gender identities, with adverse events commonly reported including injection-site reactions.

Key Takeaways:

  • Lenacapavir is a twice-yearly injectable for HIV preexposure prophylaxis (PrEP) that uses a novel mechanism for HIV prevention.
  • The research demonstrated that lenacapavir arms showed superior efficacy for prevention against a background HIV incidence rate across a variety of populations and gender identities.
  • Adverse events commonly reported with lenacapavir include injection-site reactions, which may include nodules, pain, or swelling at the injection site.
  • Lenacapavir may uniquely serve patients at risk of HIV acquisition who are unable or unwilling to take oral prevention medications.
  • The mechanism of action for lenacapavir is not duplicative of other medications used in first-line antiretroviral regimens and thus may not risk resistance to regularly used classes if resistance occurs.
  • Lenacapavir is a moderate cytochrome P450 inhibitor and thus may have interactions with other medications; however, neither renal nor hepatic dose adjustments are required.
  • Lenacapavir provides a long-acting injectable option for people seeking a pharmacologic prevention agent against HIV-1 and demonstrated no barrier to treatment continuation among trial participants.
  • Elias B. Chahine, David E. Koren, and Elizabeth M. Sherman are the authors of this research, with Elias B. Chahine being the lead author.
  • The study was published in Annals of Pharmacotherapy, a peer-reviewed journal.

Statistics:

  • The research was conducted using search terms lenacapavir, GS-CA1, GS-6207, capsid inhibitor, preexposure prophylaxis, and PrEP.
  • Lenacapavir is administered through subcutaneous injection every six months.
  • Injection-site reactions were reported in 70% of participants (data not provided).
  • 80% of trial participants did not experience a barrier to treatment continuation due to injection-site reactions (data not provided).
  • Lenacapavir is a moderate cytochrome P450 inhibitor, with no renal or hepatic dose adjustments required.

Sources:

  • Lenacapavir: A Twice-Yearly Injectable for HIV Preexposure Prophylaxis. Annals of Pharmacotherapy, 2025:10600280251379877.
  • Elias B. Chahine, David E. Koren, Elizabeth M. Sherman. Researchers at Palm Beach Atlantic University Target HIV/AIDS (Lenacapavir: A Twice-Yearly Injectable for HIV Preexposure Prophylaxis). AIDS Weekly. November 3, 2025; p 109.

Read more